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Abstract
Objectives—To fabricate biodegradable polydioxanone (PDS II®) electrospun periodontal drug 
delivery systems (hereafter referred to as matrices) containing either metronidazole (MET) or 
ciprofloxacin (CIP) and to investigate the effects of antibiotic incorporation on both non-
periodontitis and periodontitis related bacteria.
Materials and methods—Fibrous matrices were processed from PDS polymer solution by 
electrospinning. Antibiotic-containing PDS solutions were prepared to obtain four distinct groups: 
5 wt.% MET, 25 wt.% MET, 5 wt.% CIP, 25 wt.% CIP. Pure PDS was used as a control. High 
performance liquid chromatography (HPLC) was done to evaluate MET and CIP release. Dual-
species biofilms formed by Lactobacillus casei (Lc) and Streptococcus salivarius (Ss) were grown 
on the surface of all electrospun matrices. After 4 days of biofilm growth, the viability of bacteria 
on biofilms was assessed. Additionally, antimicrobial properties were evaluated against 
periodontopathogens Fusobacterium nucleatum (Fn) and Aggregatibacter actinomycetemcomitans 
(Aa) using agar diffusion assay.
Results—A three-dimensional interconnected porous network was observed in the different 
fabricated matrices. Pure PDS showed the highest fiber diameter mean (1158±402 nm) followed 
in a descending order by groups 5 wt.% MET (1108±383 nm), 25 wt.% MET (944±392 nm), 5 wt.
% CIP (871±309 nm), and 25 wt.% CIP (765±288 nm). HPLC demonstrated that groups 
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containing higher amounts (25 wt.%) of incorporated drugs released more over time while those 
with lower levels (5 wt.%) the least. No inhibitory effect of the tested antibiotics was detected on 
biofilm formation by the tested non-periodontitis related bacteria. Meanwhile, CIP-containing 
matrices inhibited growth of Fn and Aa.
Conclusion—CIP-containing matrices led to a significant inhibition of periodontal pathogens 
without negatively impairing the growth of periodontal beneficial bacteria.
Clinical relevance—Based on the proven in vitro inhibition of periodontitis-related bacteria, 
future in vivo research using relevant animal models is needed to confirm the effectiveness of 
these drug delivery systems.
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Introduction
Antimicrobials have been used as an adjunct to periodontal procedures, such as surgery and 
mechanical debridement of root surfaces in an effort to reduce bacterial recolonization of 
root and tissue surfaces [1]. Metronidazole is one of the most frequently indicated antibiotics 
for the treatment of periodontal disease [2]. However, given the increased microbial 
resistance related to its use [3–4], fluoroquinolones, such as ciprofloxacin, have been 
suggested as a potential substitute.
It is well established that the long-term use of antimicrobials might eradicate normal flora, 
which induces an imbalance in microbial composition by killing predominantly susceptible 
strains and selecting resistant ones [5]. The presence of normal microbiota is essential for 
health maintenance, since it acts as a barrier protecting the host from exogenous microbial 
colonization as well as from already present potential pathogens [6]. Nonetheless, it is 
expected that the eradication of normal microbiota might create conditions for emergence 
and colonization of opportunistic and resistant pathogens posing an increased risk to disease 
development. In terms of oral health, it has been suggested that some oral commensal 
microorganisms, such as Lc and Ss, might have an antagonistic relationship with some 
periodontal pathogens [7–8].
Guided tissue regeneration (GTR) membranes have also been adopted in periodontal 
treatment to promote tissue regeneration by avoiding migration of epithelial cells into the 
periodontal pocket [9]. Interestingly, the incorporation of metronidazole to these membranes 
[10] has given promising results in terms of inhibition of Porphyromonas gingivalis (Pg) 
growth [9]. In this context, a study has shown that the use of localized drug delivery systems 
for the treatment of periodontal disease resulted in lower selection of resistant species when 
compared to systemically delivery drug systems [11]. Accordingly, the use of a periodontal 
biodegradable matrix able to release antimicrobials directly to the gum surface without 
systemic drug exposure seems to be a wise approach preventing both bacteria resistance 
[12–13] and drug related systemic side-effects [14]. Moreover, it is highly desirable that this 
system does not interfere with the growth of oral commensal microorganisms. Therefore, the 
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purpose of this work was to fabricate biodegradable polydioxanone (PDS II®) based 
electrospun periodontal drug delivery systems (hereafter referred to as matrices) containing 
either metronidazole (MET) or ciprofloxacin (CIP) and to investigate the effects of 
antibiotic incorporation on both periodontopathogens and commensal oral bacteria.
Materials & Methods
Materials
Violet colored polydioxanone (PDS II®, Ethicon Inc., Somerville, NJ) monofilament 
surgical sutures were used. 1,1,1,3,3,3-hexafluoro-2-propanol (HFP, Sigma-Aldrich, St. 
Louis, MO) was purchased and employed as a solvent for PDS II®. Therapeutic agents (i.e., 
metronidazole and ciprofloxacin) were obtained from Sigma-Aldrich. The distinct bacteria, 
namely Lc (ATCC 4646), Ss (ATCC 25975), Fn (ATCC 10953) and Aa (ATCC 33384) 
were obtained from American Type Culture Collection (ATCC). Tryptic Soy Broth (TSB) 
culture media, Rogosa agar and Columbia Blood Agar base were obtained from Difco 
(Sparks, MD, USA). Sucrose, phosphate buffer saline (PBS), sodium chloride and 
paraformaldehyde were obtained from Fisher Scientific (Fair Lawn, NJ, USA). Defibrinated 
sheep blood was obtained from Carolina Biological Supply (Burlington, NC, USA). 
Hexamethyldisilazane (HMDS) was obtained from Sigma-Aldrich. All materials and 
chemicals were used as-received without any additional purification.
Electrospinning of nanofibrous antibiotic-containing matrices
An in-house conventional electrospinning system consisting of a (1) a high-voltage source 
(ES50P-10W/DAM, Gamma High-Voltage Research Inc., FL), (2) a syringe pump (Legato 
200, KD Scientific Apparatus, Holliston, MA), and a (3) grounded stainless steel collecting 
drum (ϕ = 4 cm) connected to a high-speed mechanical stirrer (BDC6015, Caframo, 
Wiarton, ON) was employed to obtain distinct nanofibrous matrices [9, 10]. Briefly, after 
needles removal, PDS pieces (~ 3 cm in length) were placed in a glass vial containing 
methylene chloride (Sigma-Aldrich) to eliminate the violet dye [15]. Subsequently, clear 
PDS was dissolved at 100 mg mL−1 overnight in HFP under stirring conditions [15]. 
Antibiotic-containing (5 and 25 wt.% based on the weight of PDS) solutions made by adding 
either one of the drugs directly to the PDS solution were prepared under vigorous stirring 
overnight to obtain four distinct experimental groups of antibiotic-containing fibers as 
follows: 5 wt.% MET, 25 wt.% MET, 5 wt.% CIP, 25 wt.% CIP. Pure PDS was also 
electrospun as a control. Pure PDS or the antibiotic-containing formulations were 
individually loaded in a plastic syringe fitted with a 27-gauge stainless steel needle and 
electrospun directly over glass slides (ϕ = 12 mm, # 12-545-80, Fisherbrand, Fisher 
Scientific, Fair Lawn, NJ, USA). The fibers were collected at room temperature (RT) on the 
aluminum foil covered rotating mandrel containing the glass slides using optimized 
parameters (i.e., 15 kV power voltage to the needle tip, 20 cm collection distance and a flow 
rate of 1 ml h−1). Samples were kept at RT for 2 days in a vacuum desiccator to remove any 
residual solvent. A similar procedure was carried out to obtain nanofibrous matrices over 
aluminum foil only to be used in both the antibiotic release and agar diffusion assays. The 
average fiber diameter was calculated based on three distinct SEM micrographs and a total 
of 90 measurements using an image analysis software (ImageJ, NIH, Bethesda) [10]. 
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Electrospun fiber morphology was imaged at 15 keV under a scanning electron microscope 
(SEM, JSM-5310LV, JEOL, Tokyo, Japan) after mounting and sputter coating with Au-Pd.
In-vitro antibiotic release profile
The antibiotic-containing electrospun matrices were cut into 1 × 1 cm2 squares. The drug 
content was calculated as a function of matrices weight [16]. Each sample (n=4) was 
incubated in 20.0 mL of PBS at 37 °C. 1 mL aliquots of each sample were collected at days 
1, 3, and 7. Equal amounts of fresh PBS were added back to the incubation media following 
collection of each sample to maintain the same volume [16]. High performance liquid 
chromatography (HPLC) equipped with a UV-Vis detector (Perkin-Elmer, Shelton, CT, 
USA) was used to determine the drug content using maximal absorption peaks for CIP and 
MET at 275 and 280 nm, respectively. CIP and MET standards were run on the HPLC at 
known concentrations. Linear calibration curves were used to calculate antibiotic 
concentrations in the aliquots. Antibiotic release (%) was then calculated based on the initial 
weight of the drug incorporated in the matrices [16]. Data are given as the mean value plus 
or minus the standard deviation (±SD) of the mean.
In-vitro biofilm model – Non-periodontitis related bacteria
Dual-species biofilms were grown on the surface of all electrospun samples. Glass slides 
containing PDS matrices were mounted using wax on acrylic cubes attached to the lid of 24-
well cell culture plates (Fig. 1a). Prior to biofilm formation, mounted samples were 
disinfected by immersion in 70% ethanol for 30 min and by exposure to ultra-violet light for 
2 h. For biofilm formation, Lc and Ss were cultivated on Columbia Blood Agar (CBA) 
supplemented with 5% of sheep blood. Colony-forming units (CFU) were transferred from 
CBA plates to tubes containing TSB supplemented with sucrose and incubated at 37°C with 
5% TSB supplemented with 5% sucrose was then added to each well of the culture plate. An 
aliquot of 500 μL of a multispecies suspension formed by aliquots of same optical density of 
the above mentioned strains [17] was added to each well and the plate was kept under 
constant agitation during 2 h at 37°C. Matrices were then transferred to another plate 
containing fresh artificial saliva [18] and kept at 37°C and 5% pCO2.
After approximately 16 h, matrices were transferred to a new plate containing TSB 
supplemented with 5% sucrose and incubated at 37°C and 5% pCO2 for 45 min. They were 
then dip-washed 3 times in sterile saline (0.9% NaCl), immersed in fresh artificial saliva and 
incubated at 37°C, 5% pCO2. The same procedure was repeated 4 and 8 h later to mimic the 
feast and famine periods present in oral cavity. The matrices were then transferred back to 
the same saliva provided early in the morning. This protocol was repeated for the following 
3 days.
Subsequent to biofilm formation, electrospun matrices (n=3/group) were aseptically 
removed from the lids and individually transferred to tubes containing 1 mL of sterile 0.9% 
NaCl. The biofilm suspension was vortexed for 30 seconds and sonicated for 30 seconds at 
7W. Aliquots were inoculated on CBA plates for counts of total bacteria and Ss and Rogosa 
SL agar for counts of Lc using a spiral plater. Plates were incubated at 37°C for 48 h under 
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5% pCO2. Colony-forming units (CFU) were examined under stereomicroscope and the 
results expressed as CFU/mL.
After biofilm formation, electrospun matrices (n=2/group) were fixed with 4% 
paraformaldehyde for 30 min and rinsed once in sterile 1× PBS for 5 min. Samples were 
initially dehydrated in a graded ethanol series from 50% to 100%, dried using 
ethanol:HDMS solutions of 3:1, 1:1 and 1:3 and finally in 100% HMDS [19]. The samples 
were dried at RT overnight and stored in a vacuum desiccator. Samples were imaged at 15 
keV under a SEM after mounting and sputter coating with Au-Pd [19].
Agar diffusion
The agar diffusion test was used to demonstrate the antimicrobial effect of antibiotic-
containing electrospun matrices on periodontopathogens, namely Fn and Aa. Sterile 6 mm 
disk-shaped (n=4) samples of all experimental groups and the control were placed on blood 
agar plates containing bacterial lawns of Fn and Aa [19, 20]. 5 days after incubation the 
inhibition zones (in mm) were measured [19, 20].
Statistical analysis
Analysis of variance (ANOVA) was used to determine the effect of each tested condition on 
counts of viable cells on biofilms and inhibition zones. One-way ANOVA followed by 
Tukey’s multiple comparisons procedure were used to compare the groups for differences in 
bacterial counts and inhibition zones. Analyses were performed on the natural logarithm of 
the data to satisfy the ANOVA assumptions. Statistical significance was accepted at the 
p<0.05 level.
Results
Representative SEM micrographs of PDS and antibiotic-containing electrospun fibers are 
presented in Figure 1(B–D). A three-dimensional interconnected porous network was 
observed in all fabricated electrospun matrices. Electrospun fiber diameter for the PDS 
samples with or without the antimicrobial presented a submicron array with values ranging 
from 477 nm to 1560 nm. Pure PDS showed the highest fiber diameter mean (1158±402 nm) 
followed in a descending order by groups 5 wt.% MET (1108±383 nm), 25 wt.% MET 
(944±392 nm), 5 wt.% CIP (871±309 nm), and 25 wt.% CIP (765±288 nm).
Antibiotic release profiles from each group of electrospun matrices containing either MET 
or CIP were examined using HPLC. Figure 2a presents the mean amount of drug released 
(in μg) at 1, 3, and 7 days. Groups containing higher amounts (i.e., 25 wt.%) of incorporated 
drugs released more over time while those with lower levels (i.e., 5 wt.%), the least. 
Moreover, Figure 2a shows that 5 wt.% CIP released (~ 75 μg) approximately three times 
more drug over the 7 days period when compared to its MET counterpart (~ 25 μg). It is 
interesting to note a similar pattern of drug release, in other words, when comparing 5 wt.% 
and 25 wt.% concentrations, both MET and CIP yielded approximately four (5 and 25 wt. 
MET) and five (5 and 25 wt.% CIP) times more drug. Figure 2b shows the cumulative drug 
release as a percentage of the total weight recorded prior to the study. The overall 
percentage of drug released by each group began to diverge after 72 h. After 7 day 5 wt.% 
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CIP had a cumulative release of about 92%, as opposed to ~ 40%, ~ 30%, and 12% 
respectively for 25 wt.% CIP, 5 wt.% MET, and 25 wt.% MET.
In respect to bacterial cell viability, no inhibitory effect of the tested drugs was detected on 
biofilm formation by the tested non-periodontitis related bacteria. SEM images showed the 
colonization of PDS matrices by the dual-species biofilm (Figure 3a–c). No significant 
differences in counts of Lc and Ss were found among the tested conditions (Figure 3d). Agar 
diffusion data revealed that CIP-containing matrices inhibited growth of both Fn and Aa. 
Figure 4 shows clearly a dose dependent inhibition for Fn (p= 0.04). MET-containing 
matrices had no effect on Fn growth, whereas dose dependent inhibition was detected for Aa 
(p< 0.0003). Overall, MET was less effective than CIP for growth inhibition of Aa.
Discussion
Normal flora of human oral cavity is comprised by approximately seven hundred species 
[21]. These different strains interact with the environment and each other by synergistic or 
antagonistic interactions [22], which modulate the metabolic function of the microbial 
community and are vital for the maintenance of the ecological microbial balance in that 
specific ecosystem. However, the prolonged and indiscriminate use of systemically used 
antimicrobials may disrupt this microbial balance by the selecting resistant strains [5]. 
Therefore, site-specific drug-delivery system for treatment of periodontal disease should not 
impair the growth of unrelated periodontal pathogenic bacteria. As expected, our data 
clearly suggested that under the concentrations used in the present study there was no 
detectable effect of the tested antimicrobials on counts of Lc and Ss (Figure 3).
In terms of interspecies interactions, there is evidence showing the importance between the 
natural interplay between oral bacteria and healthy environments. Koll-Klais and colleagues 
[7] showed that Lactobacilli spp. inhibited the growth of periodontal disease associated-
microorganisms, such as Aa, Pg and Prevotella intermedia (Pi) [23]. Additionally, it has 
been shown that S. salivarius interferes with the colonization of hard tissues and epithelial 
cells by Aa [24–25] and with the colonization of surfaces by Pg [8]. The importance of 
commensal microbiota on oral health status has also been suggested by Suci & Young [26] 
that verified unaffected levels of S. sanguinis after continued use of ciprofloxacin prevents 
further establishment of a mature Aa biofilm. Maintaining the viability of these 
“antagonistic” bacteria using the tested drug-delivery system provides an additional effect to 
the mechanical treatment, since it could impair further hard- and soft- tissue recolonization 
by periodontal pathogens.
In a previous study carried out by Bottino and colleagues [19] antibacterial properties of the 
MET- and CIP-containing electrospun matrices against Pg and Ef were evaluated using both 
biofilm and agar diffusion assays. Here, CIP and MET were tested on the growth inhibition 
of two other bacteria involved in periodontal infections, Fn and Aa. The agar diffusion test 
has proved the efficacy of CIP-containing matrices towards bacteria used, placing it as a 
universal antimicrobial which could be used in eradication of both endodontic and 
periodontal infections.
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Successful drug release from the electrospun matrices containing MET and CIP were 
observed through HPLC experiments, agreeing with previous results [19]. Considerable 
similarities in fiber diameter and morphology amongst the groups suggest these differences 
are not likely due to the structure of the matrices. More importantly, other factors including 
but not limited to degree of drug hydrophilicity, drug molecular weight, optimal pH for 
release, drug-matrix physicochemical interactions are known [16, 19] to play a role on 
kinetics of drug release and therefore deserve further investigation. A sustained drug release 
was seen for 5 wt.% MET, 5 wt.% CIP and 25 wt.% MET (Figure 2a) over 7 days. Although 
one might consider a week a relatively short period of time, current commercially available 
products (e.g., ELYZOL®, a metronidazole-containing gel) are normally applied over 7 day 
periods, normally two applications within 6 months of initial therapy [27]. Taken together, 
among the drug-containing matrices evaluated, it is safe to say, based on the HPLC data, 
that the amount of drugs released are well above the minimum inhibitory concentration 
(MIC) of the periodontopathogens (Fn – MET sensitive at MIC 0.2–0.4 μg, and Aa – 
sensitive to CIP at MIC below 1 μg) [28, 29].
Current adjunct treatments of periodontal disease commonly paired with scaling and root 
planning (SRP) lack discriminatory advantage against the culprit pathogens. A recent meta-
analysis demonstrates the importance of adjunct treatment in dealing with periodontal 
disease [30]. An increasing reliance on adjunct treatments to prevent further infection 
necessitates comparisons to what is currently available. One group investigating periodontal 
disease and local tetracycline therapy, utilizing Actisite®, described its broad number of 
bacterial targets and the negative impact on some potentially beneficial bacteria. This is in 
addition to an increased selection for tetracycline resistant pathogenic bacteria detectable in 
as little as 2 weeks, such as Pg and Aa, which persisted after six months of treatment [31]. 
Another potential supplemental treatment utilizing 25% MET incorporated into a gel, 
Elyzol®, has been shown to eliminate some periodontal pathogens but was unable to remove 
Aa in a clinical setting [32, 33]. This could be attributable to its quick diffusion and inability 
to apply consistent local antibiotic treatment.
The structure and composition of our electrospun matrices provide a valuable addition to 
current adjunct treatments for periodontitis. Most importantly, the combination of antibiotics 
and the release by a stable polymer-based electrospun matrix allows for extended local 
treatment. Our system is derived from a biocompatible, FDA-approved biodegradable 
polymer (i.e., polydioxanone) commonly used in medical and dental applications as suture 
material. According to the literature [34], upon degradation, 50% of the suture strength is 
reduced after three weeks, and by six months the polymer is fully resorbed with low 
inflammatory response when compared to other polymers such as (poly(glycolic-co-lactic 
acid) and poly(glycolic acid)). Hence, this drug delivery system allows for a more targeted 
elimination of harmful bacteria over some broad spectrum antibiotic treatments available. 
Furthermore, this lowers the potential for antibiotic selection of dangerous bacteria based on 
resistance in the periodontal environment. We hypothesize that under this condition, 
periodontal pockets could be colonized by these antagonistic microorganisms and reduce the 
competitive advantage of periodontal pathogens. This outcome is desirable given that it 
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could help promote tissue healing. It would also avoid commensal microorganisms of 
normal flora from indiscriminate elimination.
Conclusions
The presence of the tested antimicrobials did not impair the growth of periodontal beneficial 
bacteria; however it demonstrated an inhibitory effect on periodontopathogens. Future in 
vivo research using relevant animal models is needed to confirm the effectiveness of these 
drug delivery systems before its clinical use as a potential adjunct to SRP in the treatment of 
periodontal disease.
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Fig. 1. 
(a) Macrophotograph of the dual-species biofilm experimental set up on modified 24-wells 
tissue culture plates. Note the distinct PDS-based nanofibrous samples that were electrospun 
directly on cover borosilicate glass (solid arrow) slips attached to acrylic blocks (dotted 
arrow) using dental wax previously glued to the lid of the tissue culture plate. Representative 
SEM micrographs (b–d) of electrospun PDS matrices. (b) PDS control, (c) PDS + 25 wt.% 
MET, and (d) PDS + 25 wt.% CIP. Note the three-dimensional nanofibrous structure with an 
evident interconnected porous network.
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Fig. 2. 
(a) Mean drug release ± SD (in μg) and the (b) percentage of drug release from the 
antibiotic-containing PDS-based electrospun matrices based on initial sample weight.
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Fig. 3. 
Representative SEM micrographs of the electrospun PDS matrices following exposure to the 
dual-species biofilm. (a) PDS control, (b) PDS + 25% MET, and (c) PDS + 25% CIP. Note 
the presence of biofilm over the nanofibrous structure regardless of the material 
composition. (d) Mean counts of viable cells with error bars indicating SD (CFU/mL) on 
biofilms. No significant differences in counts of L. casei and S. salivarius were found among 
the tested conditions (p>0.05).
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Fig. 4. 
(a) Growth inhibition of Aa and Fn following 5 days exposure to electrospun matrices 
incorporated with 5 or 25 wt.% of MET or CIP. *represents a statistical difference of groups 
tested against Aa in comparison to pure PDS used as a negative control. designates a 
statistical difference of groups tested against Fn and the control. Data was generated from a 
one-way ANOVA followed by Tukey’s (p<0.05). (b–c) Representative macrophotographs 
showing growth inhibition of Aa and Fn, respectively.
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